isolution - What areas of the optical market do you see the greatest need for new drugs and what drugs do you see as being promising in those areas. Nice to see you posting.
isolution: is there any particular reason for your interest in the Retaane news?
What do you think of OXGN’s still being in preclinical after all this time development on their CA4P eye drops for AMD? Do you give them a realistic chance of making these eye drops work in humans as a maintenance treatment following an intravitreal loading dose (presumably with periodic boosters). T.i.a. Dew
Retaane is MIA in Alcon’s quarterly PR, and this is the first time that’s happened in at least five years. Alcon may finally be acknowledging that, even if Retaane were somehow approvable for wet AMD, it probably wouldn’t be worth launching. (Retaane may yet have a place in dry AMD, but the ongoing studies in that indication won’t be done until the next decade.)
Market Data 
Markets 
AI
